Correction to: Patterns and predictors of registration and participation at a supportive care program for prostate cancer survivors
The name of Stirling Bryan was incorrectly captured in the original manuscript.
Authors: Demers AA, Brenner DR, Smith L, Shaw A Abstract Examining incidence trends of all cancers combined in order to understand cancer trends can be misleading, as patterns can vary across individual cancer types. This paper highlights findings on trends over time from Canadian Cancer Statistics 2019, as measured by the annual percent change (APC) of age-standardized incidence rates. Among the results were a recent increase in thyroid cancer in males (APC: 6.4%, 1997-2015), as well as decreases in prostate cancer (APC: -9.1%, 2011-2015) and cervical cancer (APC: -3.3%, 2010-2015). PMID: 31729314 [PubMed - in process]
Promoting prostate HDR in US would not be bad. scarbrtj said: In theory based on this chart could single fraction prostate HDR pay $23K global? If so look out for a prostate HDR renaissance in the US. CMS is, wittingly or unwittingly, massively incentivizing (and disincentivizing) certain treatment paradigms with this new model. For better or worse! Click to expand...
PROSTATE cancer is the most common type of cancer in men in the UK, and because there ’s currently no cure, it’s important to be aware of the risks for developing the disease. According to studies, how you sleep can increase your risk of prostate cancer.
Minimizing the overdiagnosis and overtreatment of localized prostate cancer is a huge challenge for both patients and health care systems. Evidence now supports the role of prebiopsy multiparametric magnetic resonance imaging (mp-MRI) as a triage tool.
Japanese and German researchers are reporting early success with a PET imaging...Read more on AuntMinnie.comRelated Reading: Ga-68 PSMA PET/MRI, mpMRI work for prostate cancer analysis PSMA-PET/CT most effective for recurrent prostate cancer SNMMI: PSMA-PET helps guide prostate cancer therapy Could Ga-68 PSMA PET become essential for prostate cancer? Ga-68 PSMA PET/CT for prostate wins Australian favor
ConclusionApalutamide had manageable safety profile, without any DLT or any new safety signals, and favourable efficacy in Japanese mCRPC patients. Thus, it was ascertained to be an adequate dosage regimen in Japanese mCRPC patients.Trial registrationClinicalTrials.gov identifier: NCT02162836.
Journal of Proteome ResearchDOI: 10.1021/acs.jproteome.9b00587
In this study, we report a novel 3D printed microfluidic device functionalized with anti-EpCAM (epithelial cell adhesion molecule) antibodies to isolate CTCs from human blood samples. A 3D printing technology was utilized with specially designed interior structures to fabricate a microfluidic device with high surface area and fluid flow manipulation, increasing the capture efficiency of tumor cells. These devices with the optimal flow rate (1 mL/h) and channel length (2 cm) were demonstrated to test three kinds of EpCAM positive cancer cell lines (MCF-7 breast cancer, SW480 colon cancer, and PC3 prostate cancer), and o...
This study demonstrated that FA-PMo4V8 is simply designed and accurate in colorimetric detection of urinary sarcosine, which could be useful for clinical applications.Graphical Abstract
Prostate Cancer and Prostatic Diseases, Published online: 18 November 2019; doi:10.1038/s41391-019-0187-5Water vapor thermal therapy to alleviate catheter-dependent urinary retention secondary to benign prostatic hyperplasia